Why the study?
Does oral testosterone undecanoate improve myocardial perfusion and vascular function in men with coronary heart disease and low plasma testosterone?
Does oral testosterone undecanoate improve myocardial perfusion and vascular function in men with coronary heart disease and low plasma testosterone?
Oral testosterone undecanoate had selective and modest enhancing effects on perfusion in myocardium supplied by unobstructed coronary arteries and decreased basal arterial stiffness in men with CHD and low testosterone.
Answers are grounded in this paper and cite their sources.
Regional perfusion gains and stiffness reduction without global change advise against routine use; extends RCT evidence for targeted effects in hypogonadal CHD.
Intracoronary testosterone infusions induce coronary vasodilatation and increase coronary blood flow. Longer term testosterone supplementation favorably affected signs of myocardial ischemia in men with low plasma testosterone and coronary heart disease. However, the effects on myocardial perfusion are unknown. Effects of longer term testosterone treatment on myocardial perfusion and vascular function were investigated in men with CHD and low plasma testosterone. Twenty-two men (mean age 57 ± 9 [SD] years) were randomly assigned to oral testosterone undecanoate (TU; 80 mg twice daily) or placebo in a crossover study design. After each 8-week period, subjects underwent at rest and adenosine-stress first-pass myocardial perfusion cardiovascular magnetic resonance, pulse-wave analysis, and endothelial function measurements using radial artery tonometry, blood sampling, anthropomorphic measurements, and quality-of-life assessment. Although no difference was found in global myocardial perfusion after TU compared with placebo, myocardium supplied by unobstructed coronary arteries showed increased perfusion (1.83 ± 0.9 vs 1.52 ± 0.65; p = 0.037). TU decreased basal radial and aortic augmentation indexes (p = 0.03 and p = 0.02, respectively), indicating decreased arterial stiffness, but there was no effect on endothelial function. TU significantly decreased high-density lipoprotein cholesterol and increased hip circumference, but had no effect on hemostatic factors, quality of life, and angina symptoms. In conclusion, oral TU had selective and modest enhancing effects on perfusion in myocardium supplied by unobstructed coronary arteries, in line with previous intracoronary findings. The TU-related decrease in basal arterial stiffness may partly explain previously shown effects of exogenous testosterone on signs of exercise-induced myocardial ischemia. Intracoronary testosterone infusions induce coronary vasodilatation and increase coronary blood flow. Longer term testosterone supplementation favorably affected signs of myocardial ischemia in men with low plasma testosterone and coronary heart disease. However, the effects on myocardial perfusion are unknown. Effects of longer term testosterone treatment on myocardial perfusion and vascular function were investigated in men with CHD and low plasma testosterone. Twenty-two men (mean age 57 ± 9 [SD] years) were randomly assigned to oral testosterone undecanoate (TU; 80 mg twice daily) or placebo in a crossover study design. After each 8-week period, subjects underwent at rest and adenosine-stress first-pass myocardial perfusion cardiovascular magnetic resonance, pulse-wave analysis, and endothelial function measurements using radial artery tonometry, blood sampling, anthropomorphic measurements, and quality-of-life assessment. Although no difference was found in global myocardial perfusion after TU compared with placebo, myocardium supplied by unobstructed coronary arteries showed increased perfusion (1.83 ± 0.9 vs 1.52 ± 0.65; p = 0.037). TU decreased basal radial and aortic augmentation indexes (p = 0.03 and p = 0.02, respectively), indicating decreased arterial stiffness, but there was no effect on endothelial function. TU significantly decreased high-density lipoprotein cholesterol and increased hip circumference, but had no effect on hemostatic factors, quality of life, and angina symptoms. In conclusion, oral TU had selective and modest enhancing effects on perfusion in myocardium supplied by unobstructed coronary arteries, in line with previous intracoronary findings. The TU-related decrease in basal arterial stiffness may partly explain previously shown effects of exogenous testosterone on signs of exercise-induced myocardial ischemia. Cross-sectional studies suggest an inverse association between coronary heart disease (CHD) incidence and/or severity and endogenous testosterone levels irrespective of age,1Wu F.C. von Eckardstein A. Androgens and coronary artery disease.Endocr Rev. 2003; 24: 183-217Crossref PubMed Scopus (525) Google Scholar and testosterone treatment increases coronary blood flow and improved signs on myocardial ischemia in men with CHD.2Webb C.M. McNeill J.G. Hayward C.S. de Ziegler D. Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary artery disease.Circulation. 1999; 100: 1690-1696Crossref PubMed Scopus (390) Google Scholar, 3English K.M. Steeds R.P. Jones T.H. Diver M.J. Channer K.S. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study.Circulation. 2000; 102: 1906-1911Crossref PubMed Scopus (476) Google Scholar The aim of the present study was to investigate the hypothesis that longer term oral testosterone undecanoate (TU) treatment beneficially affects myocardial perfusion in men with established CHD and low testosterone. Second, we investigated effects on vascular and endothelial function, selected metabolic risk factors for CHD, quality of life, and angina symptoms. Men aged 40 to 75 years with angiographically proven CHD (≥70% lesion in ≥1 major coronary artery or major branch) were recruited from the outpatient departments, cardiac catheterization lists, and hospital databases of the Royal Brompton and Harefield Hospitals, London, United Kingdom. All patients had plasma testosterone ≤12 nmol/L and normal prostate-specific antigen (normal range 0 to 4 μg/L). Exclusion criteria included myocardial infarction, coronary intervention, or thoracic or abdominal surgery in the previous 3 months; hypertension; history of testosterone treatment or similar hormone therapy; hemoglobin >16 g/dl; hematocrit >50%; history of hormone-dependent cancer; permanent pacemaker; intolerance of confined spaces; or participation in another research study within the previous 60 days. The study complied with the Declaration of Helsinki, the protocol was approved by the local research ethics committee, and all patients gave written informed consent. The study used a randomized, placebo-controlled, crossover design. After consenting to the study, a screening blood sample was obtained to measure serum testosterone, prostate-specific antigen, and full blood count. Patients fulfilling the inclusion criteria then returned for a randomization visit, at which anthropomorphic measurements were obtained, quality-of-life questionnaires were completed, and study drug was dispensed (oral TU, 80 mg twice daily [Andriol Testocaps, Organon, Oss, The Netherlands] or identical placebo). After 8 weeks, an evaluation visit was conducted that included measurement of myocardial perfusion, endothelial function, quality-of-life assessment, and blood sampling for measurement of hormone, lipid, and hemostatic profiles. Patients then crossed over to the opposite treatment and returned for identical repeated testing after an additional 8 weeks at the same time of day as the first evaluation visit. Patients completed a symptom diary throughout the study. Patients were permitted to use current antianginal therapy throughout the randomized treatment period, but stopped vasoactive therapy (including statins) for 1 week before each evaluation visit. Sublingual glyceryl trinitrate was permitted for treatment of anginal attacks during this time. However, if used on the day of the evaluation visit, it was rescheduled. Patients fasted for ≥6 hours, and caffeine-containing beverages were prohibited for ≥12 hours before each evaluation visit. All cardiovascular magnetic resonance (CMR) studies were performed on a 1.5-Tesla scanner (Siemens Sonata, Siemens, Germany) with a 4-channel body-array coil. For each study, first-pass myocardial perfusion at rest and with adenosine stress was assessed. A high-resolution saturation-recovery fast low-angle shot sequence was used (field of view read 320 to 400 mm, field of view phase 75% to 100% of the field of view read, acquired voxel size 1.3 to 1.6 × 1.3 to 1.6, slice thickness 10 mm, flip angle 10°, acquisition duration 295 ms, echo time 1.11 ms, and time from saturation pulse to beginning of imaging 63 ms). Gadolinium-diethylenetriaminepentaacetic acid was injected as a bolus at 7 ml/s using a power injector (Medrad, Cambridgeshire, United Kingdom) through an 18 G intravenous cannula. Images were acquired over 50 cardiac cycles, and patients were asked to breath-hold in end-expiration for as long as was comfortable. One midventricular short-axis slice, representative of the whole ventricle, was acquired during each cardiac cycle in diastole. The stress study was performed ≥20 minutes after the study at rest. Adenosine was infused for 4 minutes at 140 μg/kg/min before stress images were acquired. On the second visit, the short-axis slice planned to be imaged was compared with the short-axis slice from the first visit to ensure an equivalent slice was studied. Because studies were analyzed quantitatively, a dual-bolus protocol was used.4Christian T.F. Rettmann D.W. Aletras A.H. Liao S.L. Taylor J.L. Balaban R.S. Arai A.E. Absolute myocardial perfusion in canines measured by using dual-bolus first-pass MR imaging.Radiology. 2004; 232: 677-684Crossref PubMed Scopus (242) Google Scholar, 5Elkington A.G. Ablitt N.A. Yang G.Z. Firmin D.N. Pennell D.J. Interstudy reproducibility of quantitative perfusion cardiovascular magnetic resonance.J Cardiovasc Magn Reson. 2005; 7: 815-822Crossref PubMed Scopus (32) Google Scholar For both studies at rest and with stress, patients received a low-dose (0.01 mmol/kg at 0.05 mol/L) bolus of gadolinium (Omniscan; Nycomed, Lidingö, Sweden) approximately 2 minutes before a high-dose bolus of gadolinium (0.1 mmol/kg at 0.5 mol/L). This allowed an accurate arterial input function and optimized signal in the myocardium. Blood pressure (BP) and heart rate were monitored throughout each study. On both visits, left ventricular (LV) volume, function, and mass measurements were acquired using breath-hold segmented true fast imaging with steady-state precession cines according to a standard protocol.6Maceira A.M. Prasad S.K. Khan M. Pennell D.J. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance.J Cardiovasc Magn Reson. 2006; 8: 417-426Crossref PubMed Scopus (644) Google Scholar Each study was analyzed by a blinded observer using customized software (CMRtools; Cardiovascular Imaging Solutions, London, United Kingdom). For perfusion analysis, subendocardial and subepicardial myocardial borders were drawn and adjusted if necessary to compensate for cardiac and respiratory motion. Arterial input function and myocardial tissue response curves were corrected using baseline subtraction, then assumed to be linearly proportional to gadolinium concentration. An index of myocardial perfusion (a unitless measure) was calculated at rest and at stress from the respective first-pass myocardial signal intensity-time curves using Fermi deconvolution.7Jerosch-Herold M. Wilke N. Stillman A.E. Magnetic resonance quantification of the myocardial perfusion reserve with a Fermi function model for constrained deconvolution.Med Phys. 1988; 25: 73-84Crossref Scopus (360) Google Scholar Myocardial perfusion index (the ratio between stress and rest myocardial perfusion) was calculated using model-based deconvolution using the Fermi function. Each CMR image was divided into 4 (anterior, lateral, inferior, and septum), and areas of myocardium supplied by coronary arteries with and without significant (≥70% lesion) angiographically documented coronary stenosis were analyzed separately. LV mass, end-diastolic and end-systolic volumes, and ejection fraction were determined using standard manual contouring techniques. Peripheral pressure waveforms were recorded from the right radial artery using applanation tonometry (SphgmoCor PX, version 6.31; AtCor, Sydney, Australia). BP was measured noninvasively every 5 minutes throughout the tonometry study on the contralateral arm (Dinamap, GE Healthcare, Chalfont St. Giles, Buckinghamshire, United Kingdom). Immediately after each BP measurement, radial artery pulse recordings were acquired with an averaged peripheral waveform generated from 20 sequential waveforms. Corresponding central waveforms were generated using an online validated transfer function to determine central augmentation index, central pressure, and heart rate. Augmentation index was calculated as the ratio of pulse pressure at the second systolic arterial pressure waveform peak to that of the first systolic peak and is a measure of arterial stiffness. Patients underwent measurement of endothelium-dependent and -independent responses using radial artery applanation tonometry before and after salbutamol (400 μg) and sublingual glyceryl trinitrate (250 μg) as previously described.8Hayward C.S. Kraidly M. Webb C.M. Collins P. Assessment of endothelial function using peripheral waveform analysis A clinical application.J Am Coll Cardiol. 2002; PubMed Scopus Google Scholar of quality of were measured using validated the which (a or The and in a 1988; PubMed Scopus Google which cardiac (a low a P. The and of a quality of 7: PubMed Scopus Google and the P. The of 2003; PubMed Scopus Google Scholar hormone, hormone, and were measured using United and was measured using a standard United Kingdom). high-density lipoprotein and were measured using a lipoprotein cholesterol was using the of blood was measured using a standard with a United Kingdom). and were measured using an United and using was determined by the of myocardial intracoronary testosterone study showed an increase in blood flow to testosterone of approximately to C.M. McNeill J.G. Hayward C.S. de Ziegler D. Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary artery disease.Circulation. 1999; 100: 1690-1696Crossref PubMed Scopus (390) Google Scholar A difference of in myocardial perfusion index with an of 0.5 with of a power to a difference between and randomization to the 2 in for a patients were for the size of the was and no effect was found for Second, the difference between treatment was analyzed by of the second from from the first period, and a was performed to An of this compared with a is that it the effect of from the were analysis was performed using was at p are as ± or difference For myocardial perfusion each CMR image was divided into 4 Because this the of were analyzed in 2 a was used then with to for repeated from the same patients were by and of patients in in the study. approximately were of One patients for a and screening had testosterone the inclusion patients were in the study, and completed the patients were randomly but before the study drug and 1 the randomization and 1 was after a on study (TU) to for a One after the first treatment phase of and 1 for of the patients had at 1 evaluation visit are in Although of 1 was to previously used testosterone treatment 3 before In that patients had or of function. This was by testosterone or = ± 8 significantly major coronary arteries coronary artery coronary ± 3 artery ± 4 myocardial ± history BP ± BP ± rate ± ± ± mass index ± ± testosterone ± antigen ± as ± or in a as ± or levels are in TU significantly serum testosterone or of free and testosterone and levels increased p TU treatment was with a significant decrease in hormone, and hormone p testosterone ± ± ± testosterone ± ± ± ± ± compared with ± testosterone ± ± ± ± ± compared with ± ± ± compared with ± ± ± compared with ± ± ± ± hormone ± ± compared with ± hormone ± ± compared with ± as ± p compared with in a as ± Twenty-two patients had CMR for both evaluation myocardial perfusion was significantly between ± vs 1.6 ± TU vs p = or in the ± vs ± TU vs p = or ± vs 1.6 ± TU vs p = analyzed by no significant difference in perfusion was shown in the (1.83 ± vs ± TU vs placebo, p = or ± vs ± TU vs placebo, p = after for repeated However, myocardial supplied by coronary arteries without significant showed significant in the myocardial perfusion index of the (1.83 ± 0.9 vs 1.52 ± TU vs placebo, p = and in the ± vs ± TU vs placebo, p = in patients TU Myocardial supplied by coronary arteries with significant coronary showed no difference in myocardial perfusion indexes in the (1.83 ± vs ± TU vs placebo p = or ± vs ± TU vs p = Adenosine decrease heart rate or in patients had LV for both LV ejection fraction was significantly after testosterone treatment compared with placebo ± vs ± p = However, ± vs ± p = end-systolic ± vs ± p = end-diastolic ± vs ± 18 p = and mass ± vs ± p = were patients completed both endothelial function TU treatment was with significantly baseline radial augmentation (p = and aortic augmentation indexes ± vs ± TU vs placebo, p = compared with placebo, indicating a decrease in basal arterial stiffness. However, testosterone in radial augmentation indexes compared with placebo (p = no effect on endothelium-dependent in radial augmentation indexes were similar after both (p = to of an of pulse-wave A. A. M. systolic pressure in chronic of arterial PubMed Scopus Google Scholar was after TU treatment compared with placebo ± vs ± p = systolic BP was throughout the tonometry study ± vs ± TU vs p = there was no significant difference in central pulse pressure ± 10 vs ± TU vs placebo, p = or heart rate at rest ± 7 vs 60 ± 7 TU vs placebo, p = TU treatment was with significantly high-density lipoprotein cholesterol and and high-density lipoprotein ratio compared with placebo ratio decreased with and and were between and hemostatic cholesterol ± ± ± ± ± ± lipoprotein cholesterol ± ± compared with ± ± ± ± lipoprotein cholesterol ± ± ± ± ± ± lipoprotein cholesterol ± ± = compared with ± ± ± ± ± ± ± = compared with ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± as ± p compared with p = compared with in a as ± was no difference in or after treatment with TU or placebo but significantly increased after TU treatment ± vs ± TU vs placebo, p = However, hemoglobin was affected ± vs ± TU vs placebo, p = was a significant increase in hip after TU compared with placebo ± vs ± p = but no difference in ± vs ± p = ± 8 vs ± 10 p = ratio ± 0.05 vs 1 ± p = ± vs ± p = or mass index ± vs ± p = was a a increase in systolic BP ± vs ± p = there was no difference in diastolic BP ± 8 vs ± 7 p = or heart rate ± 8 vs ± 9 p = was no significant difference between for of the or and no difference in incidence of angina ± 5 vs 1 ± 2 8-week treatment period, TU vs placebo, were no to study One a was placebo and over to TU that 8 weeks of oral TU in men with CHD and low testosterone increased myocardial perfusion in myocardium supplied by unobstructed coronary arteries, perfusion in areas of myocardium supplied by coronary arteries with significant coronary was this is the first of blood flow effects of testosterone in with coronary disease in TU treatment decreased basal peripheral and central arterial stiffness, and there was a increase in LV ejection was a effect on myocardial perfusion, global endothelial function, quality of life, and angina compared with for the first time the effects of testosterone on myocardial perfusion in myocardial supplied by coronary A previous study showed that intracoronary testosterone coronary and increased coronary blood flow in unobstructed coronary arteries in patients with CHD in major coronary arteries, but flow responses were measured in significantly C.M. McNeill J.G. Hayward C.S. de Ziegler D. Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary artery disease.Circulation. 1999; 100: 1690-1696Crossref PubMed Scopus (390) Google Scholar In line with the intracoronary study, the present longer term study showed of myocardial blood flow in of myocardium that may be through effects on the coronary arteries previous intracoronary testosterone study showed no effect on coronary or coronary flow C.M. McNeill J.G. Hayward C.S. de Ziegler D. Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary artery disease.Circulation. 1999; 100: 1690-1696Crossref PubMed Scopus (390) Google Scholar However, the testosterone and of treatment used may had A previous study of perfusion CMR in patients with cardiac showed subendocardial in response to but no effect was shown in the present Yang G.Z. Firmin D.N. Collins P. Pennell D.J. subendocardial perfusion in cardiac by cardiovascular magnetic resonance 2002; PubMed Scopus Google Scholar is that we were to perfusion in myocardial with significant testosterone therapy in the longer term effects on signs of exercise-induced myocardial K.M. Steeds R.P. Jones T.H. Diver M.J. Channer K.S. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study.Circulation. 2000; 102: 1906-1911Crossref PubMed Scopus (476) Google Scholar TU-related in basal arterial stiffness that the in this effect may at in effects on vascular no effect on BP or heart However, myocardial perfusion with the effect of testosterone treatment on angina shown in both the present study and K.M. Steeds R.P. Jones T.H. Diver M.J. Channer K.S. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study.Circulation. 2000; 102: 1906-1911Crossref PubMed Scopus (476) Google Scholar in is with an increase in arterial stiffness to at in to in M. A.M. in artery stiffness and 2003; PubMed Scopus Google Scholar However, a study in men (mean age years) an inverse between endogenous serum testosterone and arterial J.L. between and arterial stiffness on hormone 2006; Scholar that oral TU treatment a effect on arterial stiffness in men with testosterone at or the of normal In of research that arterial stiffness was a of cardiovascular of aortic pulse as index of arterial stiffness in the 2006; PubMed Scopus Google Scholar, A. R.S. Arterial stiffness and risk of coronary heart disease and the 2006; PubMed Scopus Google Scholar may suggest that in the longer oral TU cardiovascular through effects on arterial stiffness. The to effects of oral TU on arterial stiffness or vascular in in shown by the present study and N. of oral of testosterone on arterial in men with coronary artery Cardiol. 2002; PubMed Scopus Google Scholar studies that and vascular and vascular 2004; Google Scholar, D.N. treatment increases function in 2005; Scholar The augmentation index measured after TU treatment be by a of decreased from an effect on and of pulse-wave from an effect on the of a BP TU treatment in a but significant increase in LV ejection fraction compared with placebo, with no difference in LV mass, volume, or end-systolic or This is in of a of decreased LV ejection fraction in patients with low endogenous free An of between endogenous hormone levels and the of coronary heart disease and the ejection fraction of the left in 2003; Google Scholar and may be by a of TU on myocardial of of cardiac 2003; Scholar was with decreased cardiac in with improved in A. T.F. Effects of and on PubMed Scopus Google Scholar effects may be by on adenosine T.F. A. The effects of on left ventricular function and cardiac in and PubMed Scopus Google Scholar However, are and additional studies are the of testosterone on cardiac function in testosterone levels increase after TU treatment TU is into the with then into blood from the A. P. levels in men after oral of testosterone or testosterone Google Scholar and into A. a Google Scholar In this first is significantly increased and hormone, and hormone decreased after TU The for the 8-week treatment was on of the longer term of of and on the vascular after K.M. Steeds R.P. Jones T.H. Diver M.J. Channer K.S. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study.Circulation. 2000; 102: 1906-1911Crossref PubMed Scopus (476) Google Scholar, of testosterone on PubMed Scopus Google Scholar to patients to weeks of and the a of 4 to 8 is that testosterone therapy for longer may testosterone treatment is to of cardiovascular that were measured in the present study, but that may myocardial perfusion and vascular function. CMR perfusion are and may the may for The in myocardial perfusion and shown were and it may be of to similar studies using perfusion techniques.
No takes yet. Share an insight, caveat, or question.
Webb et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: